Fulcrum therapeutics reports qtrly loss per share $0.71

Fulcrum therapeutics reports recent business highlights and fourth quarter and full year 2019 financial results.fulcrum therapeutics inc qtrly loss per share $0.71.fulcrum - expects existing cash, cash equivalents to be sufficient to fund operating expenses & capital expenditure requirements into q3 2021.
FULC Ratings Summary
FULC Quant Ranking